Be sure to consult a provider before starting any fasting routine
[11] [12] Currently available GLP-1 receptor agonists in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GLP-1/GIP receptor agonist
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD)
The medication's action on these receptors could theoretically influence headache susceptibility, though this remains an area requiring further research
A voxel-based morphometry study of young occasional users of amphetamine-type stimulants and cocaine